荷兰可切除胃癌患者围手术期氟尿嘧啶、亚叶酸钙、奥沙利铂和多西他赛化疗的可及性
该回顾性队列研究基于荷兰癌症登记处2015-2020年3290例可切除胃癌患者,评估围手术期化疗使用模式和FLOT方案采纳情况。FLOT方案在结果发表后从42.9%增至86.8%(p<0.0001),但各医院采纳时间不一,导致患者可及性不均衡。作者认为建立国家级指南和快速发表最终试验结果对减少实践差异至关重要。
要点
- 2015年43.6%患者接受围手术期化疗,2020年为43.5%(p=0.63)。
- FLOT方案在发表后从42.9%增至86.8%(p<0.0001),蒽环类三联方案降至0.9%(p<0.0001)。
- 62家医院中40家(64.5%)在ASCO报告至全文发表期间采纳FLOT,各院时间不一。
核心结论
- 荷兰各医院采纳FLOT方案的时间不一,导致患者对有效治疗的可及性不均衡。
- 作者认为建立国家级指南和快速发表最终试验结果对减少实践差异和确保公平治疗至关重要。
研究设计与样本
- 回顾性队列研究,纳入荷兰癌症登记处2015-2020年可切除胃癌患者(cT1-4a,XcNallcM0)。
- 共纳入3290例患者,使用描述性统计、Cochran-Armitage检验、Fisher精确检验或非配对T检验及Jonckheere-Terpstra检验分析化疗趋势和FLOT采纳情况。
主要发现
- 3290例患者中42.9%接受了新辅助治疗。
- 2015年43.6%患者接受围手术期化疗,2020年为43.5%(p=0.63)。
- 62家医院中40家(64.5%)在ASCO报告至全文发表期间采纳FLOT。
- FLOT使用率从发表前的42.9%增至发表后的86.8%(p<0.0001),蒽环类三联方案使用率降至0.9%(p<0.0001)。
- 医院体量较高与采纳时间较短相关(p=0.04),但与发表前是否采纳FLOT无关(p=0.14)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The FLOT4 trial demonstrated superior survival of perioperative chemotherapy with 5-fluorouracil, oxaliplatin, and docetaxel (FLOT) compared to anthracycline triplets for resectable gastric cancer. These results were presented at the American Society of Clinical Oncology (ASCO) congress in June 2017 and published in April 2019. However, adoption of novel treatments in clinical practice often encounters delays. This study assesses the patterns of perioperative chemotherapy utilization and FLOT uptake in clinical practice within the Netherlands. MATERIALS AND METHODS: A retrospective cohort study was conducted with resectable gastric cancer patients (cT1-4a,XcNallcM0) between 2015-2020 from the Netherlands Cancer Registry. Descriptive statistics, Cochran-Armitage tests, Fisher's exact or unpaired T-tests, and Jonckheere-Terpstra tests were used to analyze chemotherapy trends and FLOT uptake across hospitals. RESULTS: Among 3290 included patients, 42.9 % received neoadjuvant treatment. In 2015, 43.6 % of patients received perioperative chemotherapy versus 43.5 % in 2020 (p = 0.63). 40 out of 62 hospitals (64.5 %) adopted FLOT between the ASCO presentation and the full publication. FLOT increased from 42.9 % before publication to 86.8 % after publication (p < 0.0001), while anthracycline triplet use decreased to 0.9 % (p < 0.0001). Higher hospital volume was associated with fewer days to adoption (p = 0.04) but not with adoption of FLOT before publication (p = 0.14). CONCLUSION: Timing of FLOT adoption varied among Dutch hospitals, leading to unequal patient access to effective treatments. Establishing (inter)national guidelines on provisional treatment adjustment pending publication is crucial to reduce variation in access. Moreover, rapid publication of final trial results is imperative to reduce variation in practice and ensure fair patient treatment.
引用
- Geerts JFM, Pape M, Vissers PAJ, et al. Patient access to perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin and docetaxel in patients with resectable gastric cancer in the Netherlands. Eur J Cancer. 2024. PMID: 39591847. doi:10.1016/j.ejca.2024.115137
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。